Open Nav

Please submit your session questions in advance at

BioMarker Strategies, LLC

  • Jerry Parrott, BioMarker Strategies, LLC

Our mission is to enable use of live cells to personalize drug development and treatment selection for patients with solid tumor cancers.

We have developed the patented SnapPath Cancer Diagnostics System - the only diagnostics system that can generate purified populations of live solid tumor cells from live, unfixed samples in an automated and standardized manner.

SnapPath preserves molecular integrity of these living cells for ex vivo exposure to targeted therapies. This enables generation of PathMap Functional Signaling Profiles, which are highly predictive of individual solid tumor response to targeted therapies and combinations, because they are based on the dynamic signaling information available only from live cells.

This functional information is required to understand initial response and the acquired resistance that too often develops in the treatment of cancer.

  • Date:Monday, February 11
  • Time:10:15 AM - 10:30 AM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23395
  • Company Presentation - Presentation Type:Privately Funded Company
  • Goal for Presentation:Fund-raising and business development
  • Company
  • Company HQ City:Rockville
  • Company HQ State:Maryland
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$12.4 million equity capital + $6.8 million from NCI
  • Previous and Current Investors:Novit LP, Abell Foundation, CEO Jerry Parrott, Other Individuals
  • CEO/Top Company Official:Jerry Parrott, President & CEO
  • Year Founded:2006
  • Main Therapeutic Focus:Diagnostics
  • Lead Product in Development:SnapPath Cancer Diagnostics System
  • Development Phase of Primary Product:Other/Not Applicable
Jerry Parrott
BioMarker Strategies, LLC